Felice Isabel Verduyn-van Weegen - Nov 5, 2025 Form 3 Insider Report for Evommune, Inc. (EVMN)

Role: Director, 10%+ Owner
Signature: /s/ Gregory S. Moss, Attorney-in-Fact
Stock symbol: EVMN
Transactions as of: Nov 5, 2025
Transactions value $: $0
Form type: 3
Date filed: 11/5/2025, 08:11 PM
Next filing: Nov 12, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Verduyn-van Weegen Felice Isabel	Director, 10%+ Owner	C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO	/s/ Gregory S. Moss, Attorney-in-Fact	2025-11-05	0002094941

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EVMN	Series A Preferred Stock							Nov 5, 2025	Common Stock	1.95M		By LSP 7 Cooperatief U.A.	F1, F2
holding	EVMN	Series B Preferred Stock							Nov 5, 2025	Common Stock	647K		By LSP 7 Cooperatief U.A.	F2, F3
holding	EVMN	Series C Preferred Stock							Nov 5, 2025	Common Stock	773K		By LSP 7 Cooperatief U.A.	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.9557 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ("IPO"), all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
F2	These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein.
F3	The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
F4	The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.